Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The impact of tunnel mutations on enzymatic catalysis depends on the tunnel-substrate complementarity and the rate-limiting step

P. Kokkonen, M. Slanska, V. Dockalova, GP. Pinto, EM. Sánchez-Carnerero, J. Damborsky, P. Klán, Z. Prokop, D. Bednar,

. 2020 ; 18 (-) : 805-813. [pub] 20200325

Language English Country Netherlands

Document type Journal Article

Transport of ligands between bulk solvent and the buried active sites is a critical event in the catalytic cycle of many enzymes. The rational design of transport pathways is far from trivial due to the lack of knowledge about the effect of mutations on ligand transport. The main and an auxiliary tunnel of haloalkane dehalogenase LinB have been previously engineered for improved dehalogenation of 1,2-dibromoethane (DBE). The first chemical step of DBE conversion was enhanced by L177W mutation in the main tunnel, but the rate-limiting product release was slowed down because the mutation blocked the main access tunnel and hindered protein dynamics. Three additional mutations W140A + F143L + I211L opened-up the auxiliary tunnel and enhanced the product release, making this four-point variant the most efficient catalyst with DBE. Here we study the impact of these mutations on the catalysis of bulky aromatic substrates, 4-(bromomethyl)-6,7-dimethoxycoumarin (COU) and 8-chloromethyl-4,4'-difluoro-3,5-dimethyl-4-bora-3a,4a-diaza-s-indacene (BDP). The rate-limiting step of DBE conversion is the product release, whereas the catalysis of COU and BDP is limited by the chemical step. The catalysis of COU is mainly impaired by the mutation L177W, whereas the conversion of BDP is affected primarily by the mutations W140A + F143L + I211L. The combined computational and kinetic analyses explain the differences in activities between the enzyme-substrate pairs. The effect of tunnel mutations on catalysis depends on the rate-limiting step, the complementarity of the tunnels with the substrates and is clearly specific for each enzyme-substrate pair.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019423
003      
CZ-PrNML
005      
20201123123332.0
007      
ta
008      
201103s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.csbj.2020.03.017 $2 doi
035    __
$a (PubMed)32308927
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kokkonen, Piia $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
245    14
$a The impact of tunnel mutations on enzymatic catalysis depends on the tunnel-substrate complementarity and the rate-limiting step / $c P. Kokkonen, M. Slanska, V. Dockalova, GP. Pinto, EM. Sánchez-Carnerero, J. Damborsky, P. Klán, Z. Prokop, D. Bednar,
520    9_
$a Transport of ligands between bulk solvent and the buried active sites is a critical event in the catalytic cycle of many enzymes. The rational design of transport pathways is far from trivial due to the lack of knowledge about the effect of mutations on ligand transport. The main and an auxiliary tunnel of haloalkane dehalogenase LinB have been previously engineered for improved dehalogenation of 1,2-dibromoethane (DBE). The first chemical step of DBE conversion was enhanced by L177W mutation in the main tunnel, but the rate-limiting product release was slowed down because the mutation blocked the main access tunnel and hindered protein dynamics. Three additional mutations W140A + F143L + I211L opened-up the auxiliary tunnel and enhanced the product release, making this four-point variant the most efficient catalyst with DBE. Here we study the impact of these mutations on the catalysis of bulky aromatic substrates, 4-(bromomethyl)-6,7-dimethoxycoumarin (COU) and 8-chloromethyl-4,4'-difluoro-3,5-dimethyl-4-bora-3a,4a-diaza-s-indacene (BDP). The rate-limiting step of DBE conversion is the product release, whereas the catalysis of COU and BDP is limited by the chemical step. The catalysis of COU is mainly impaired by the mutation L177W, whereas the conversion of BDP is affected primarily by the mutations W140A + F143L + I211L. The combined computational and kinetic analyses explain the differences in activities between the enzyme-substrate pairs. The effect of tunnel mutations on catalysis depends on the rate-limiting step, the complementarity of the tunnels with the substrates and is clearly specific for each enzyme-substrate pair.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Slanska, Michaela $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Dockalova, Veronika $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Pinto, Gaspar P $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Centre, St. Ann's Hospital, Brno, Czech Republic.
700    1_
$a Sánchez-Carnerero, Esther M $u Department of Chemistry and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Damborsky, Jiri $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Centre, St. Ann's Hospital, Brno, Czech Republic.
700    1_
$a Klán, Petr $u Department of Chemistry and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic.
700    1_
$a Prokop, Zbynek $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Centre, St. Ann's Hospital, Brno, Czech Republic.
700    1_
$a Bednar, David $u Loschmidt Laboratories, Department of Experimental Biology and RECETOX, Faculty of Science, Masaryk University, Brno, Czech Republic. International Clinical Research Centre, St. Ann's Hospital, Brno, Czech Republic.
773    0_
$w MED00184782 $t Computational and structural biotechnology journal $x 2001-0370 $g Roč. 18, č. - (2020), s. 805-813
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32308927 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20201123123331 $b ABA008
999    __
$a ind $b bmc $g 1586200 $s 1109621
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 18 $c - $d 805-813 $e 20200325 $i 2001-0370 $m Computational and structural biotechnology journal $n Comput Struct Biotechnol J $x MED00184782
LZP    __
$a Pubmed-20201103

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...